Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality

Kathryn L. Pellegrini, Martin G. Sanda, Dattatraya Patil, Qi Long, María Santiago-Jiménez, Mandeep Takhar, Nicholas Erho, Kasra Yousefi, Elai Davicioni, Eric A. Klein, Robert Brian Jenkins, Robert Jeffrey Karnes, Carlos S. Moreno

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: To determine the prognostic potential of a 24-gene signature, Sig24, for identifying patients with prostate cancer who are at risk of developing metastases or of prostate cancer-specific mortality (PCSM) after radical prostatectomy (RP). Patients and Methods: Sig24 scores were calculated from previously collected gene expression microarray data from the Cleveland Clinic and Mayo Clinic (I and II). The performance of Sig24 was determined using time-dependent c-index analysis, Cox proportional hazards regression and Kaplan-Meier survival analysis. Results: Higher Sig24 scores were significantly associated with higher pathological Gleason scores in all three cohorts. Analysis of the Mayo Clinic II cohort, which included time-to-event information, indicated that patients with high Sig24 scores also had a higher risk of developing metastasis (hazard ratio [HR] 3.78, 95% confidence interval [CI]: 1.96-7.29; P < 0.001) or of PCSM (HR 6.54, 95% CI: 2.16-19.83; P < 0.001). Conclusions: The findings of the present study show the applicability of Sig24 for the prognosis of metastasis or PCSM after RP. Future studies investigating the combination of Sig24 with available prognostic tests may provide new approaches to improve risk stratification for patients with prostate cancer.

Original languageEnglish (US)
JournalBJU International
DOIs
StateAccepted/In press - 2017

Fingerprint

Prostatic Neoplasms
Mortality
Genes
Prostatectomy
Neoplasm Metastasis
Confidence Intervals
Neoplasm Grading
Kaplan-Meier Estimate
Survival Analysis
Gene Expression

Keywords

  • #PCSM
  • #ProstateCancer
  • Biomarker
  • Metastasis

ASJC Scopus subject areas

  • Urology

Cite this

Pellegrini, K. L., Sanda, M. G., Patil, D., Long, Q., Santiago-Jiménez, M., Takhar, M., ... Moreno, C. S. (Accepted/In press). Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality. BJU International. https://doi.org/10.1111/bju.13779

Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality. / Pellegrini, Kathryn L.; Sanda, Martin G.; Patil, Dattatraya; Long, Qi; Santiago-Jiménez, María; Takhar, Mandeep; Erho, Nicholas; Yousefi, Kasra; Davicioni, Elai; Klein, Eric A.; Jenkins, Robert Brian; Karnes, Robert Jeffrey; Moreno, Carlos S.

In: BJU International, 2017.

Research output: Contribution to journalArticle

Pellegrini, KL, Sanda, MG, Patil, D, Long, Q, Santiago-Jiménez, M, Takhar, M, Erho, N, Yousefi, K, Davicioni, E, Klein, EA, Jenkins, RB, Karnes, RJ & Moreno, CS 2017, 'Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality', BJU International. https://doi.org/10.1111/bju.13779
Pellegrini, Kathryn L. ; Sanda, Martin G. ; Patil, Dattatraya ; Long, Qi ; Santiago-Jiménez, María ; Takhar, Mandeep ; Erho, Nicholas ; Yousefi, Kasra ; Davicioni, Elai ; Klein, Eric A. ; Jenkins, Robert Brian ; Karnes, Robert Jeffrey ; Moreno, Carlos S. / Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality. In: BJU International. 2017.
@article{d98846477d004ca787a696339929bc41,
title = "Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality",
abstract = "Objectives: To determine the prognostic potential of a 24-gene signature, Sig24, for identifying patients with prostate cancer who are at risk of developing metastases or of prostate cancer-specific mortality (PCSM) after radical prostatectomy (RP). Patients and Methods: Sig24 scores were calculated from previously collected gene expression microarray data from the Cleveland Clinic and Mayo Clinic (I and II). The performance of Sig24 was determined using time-dependent c-index analysis, Cox proportional hazards regression and Kaplan-Meier survival analysis. Results: Higher Sig24 scores were significantly associated with higher pathological Gleason scores in all three cohorts. Analysis of the Mayo Clinic II cohort, which included time-to-event information, indicated that patients with high Sig24 scores also had a higher risk of developing metastasis (hazard ratio [HR] 3.78, 95{\%} confidence interval [CI]: 1.96-7.29; P < 0.001) or of PCSM (HR 6.54, 95{\%} CI: 2.16-19.83; P < 0.001). Conclusions: The findings of the present study show the applicability of Sig24 for the prognosis of metastasis or PCSM after RP. Future studies investigating the combination of Sig24 with available prognostic tests may provide new approaches to improve risk stratification for patients with prostate cancer.",
keywords = "#PCSM, #ProstateCancer, Biomarker, Metastasis",
author = "Pellegrini, {Kathryn L.} and Sanda, {Martin G.} and Dattatraya Patil and Qi Long and Mar{\'i}a Santiago-Jim{\'e}nez and Mandeep Takhar and Nicholas Erho and Kasra Yousefi and Elai Davicioni and Klein, {Eric A.} and Jenkins, {Robert Brian} and Karnes, {Robert Jeffrey} and Moreno, {Carlos S.}",
year = "2017",
doi = "10.1111/bju.13779",
language = "English (US)",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality

AU - Pellegrini, Kathryn L.

AU - Sanda, Martin G.

AU - Patil, Dattatraya

AU - Long, Qi

AU - Santiago-Jiménez, María

AU - Takhar, Mandeep

AU - Erho, Nicholas

AU - Yousefi, Kasra

AU - Davicioni, Elai

AU - Klein, Eric A.

AU - Jenkins, Robert Brian

AU - Karnes, Robert Jeffrey

AU - Moreno, Carlos S.

PY - 2017

Y1 - 2017

N2 - Objectives: To determine the prognostic potential of a 24-gene signature, Sig24, for identifying patients with prostate cancer who are at risk of developing metastases or of prostate cancer-specific mortality (PCSM) after radical prostatectomy (RP). Patients and Methods: Sig24 scores were calculated from previously collected gene expression microarray data from the Cleveland Clinic and Mayo Clinic (I and II). The performance of Sig24 was determined using time-dependent c-index analysis, Cox proportional hazards regression and Kaplan-Meier survival analysis. Results: Higher Sig24 scores were significantly associated with higher pathological Gleason scores in all three cohorts. Analysis of the Mayo Clinic II cohort, which included time-to-event information, indicated that patients with high Sig24 scores also had a higher risk of developing metastasis (hazard ratio [HR] 3.78, 95% confidence interval [CI]: 1.96-7.29; P < 0.001) or of PCSM (HR 6.54, 95% CI: 2.16-19.83; P < 0.001). Conclusions: The findings of the present study show the applicability of Sig24 for the prognosis of metastasis or PCSM after RP. Future studies investigating the combination of Sig24 with available prognostic tests may provide new approaches to improve risk stratification for patients with prostate cancer.

AB - Objectives: To determine the prognostic potential of a 24-gene signature, Sig24, for identifying patients with prostate cancer who are at risk of developing metastases or of prostate cancer-specific mortality (PCSM) after radical prostatectomy (RP). Patients and Methods: Sig24 scores were calculated from previously collected gene expression microarray data from the Cleveland Clinic and Mayo Clinic (I and II). The performance of Sig24 was determined using time-dependent c-index analysis, Cox proportional hazards regression and Kaplan-Meier survival analysis. Results: Higher Sig24 scores were significantly associated with higher pathological Gleason scores in all three cohorts. Analysis of the Mayo Clinic II cohort, which included time-to-event information, indicated that patients with high Sig24 scores also had a higher risk of developing metastasis (hazard ratio [HR] 3.78, 95% confidence interval [CI]: 1.96-7.29; P < 0.001) or of PCSM (HR 6.54, 95% CI: 2.16-19.83; P < 0.001). Conclusions: The findings of the present study show the applicability of Sig24 for the prognosis of metastasis or PCSM after RP. Future studies investigating the combination of Sig24 with available prognostic tests may provide new approaches to improve risk stratification for patients with prostate cancer.

KW - #PCSM

KW - #ProstateCancer

KW - Biomarker

KW - Metastasis

UR - http://www.scopus.com/inward/record.url?scp=85012149146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012149146&partnerID=8YFLogxK

U2 - 10.1111/bju.13779

DO - 10.1111/bju.13779

M3 - Article

JO - BJU International

JF - BJU International

SN - 1464-4096

ER -